163
Participants
Start Date
July 31, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
GS-5885 tablet
30 mg active tablet
GS-9451 tablet
two active 100 mg tablets
peginterferon alfa-2a
peginterferon alfa-2a (solution for injection) 180 µg/week
ribavirin tablet
ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
Concorde Medical Group, New York
Cornell University Gastroenterology & Hepatology, New York
North Shore University Hospital, Manhasset
Binghamton Gastroenterology, Binghamton
Digestive Disease Associates, PA, Baltimore
Metropolitan Research, Fairfax
Liver Institute of Virginia, Richmond
Digestive and Liver Disease Specialists, Norfolk
Duke University Medical Center, Durham
Cumberland Research Associates, LLC, Fayetteville
Asheville Gastroenterology Associates, P.A., Asheville
Dekalb Gastroenterology, Decatur
Gastrointestinal Specialists of Georgia PC, Marietta
Emory University, Infectious Disease Clinic, Atlanta
Digestive Healthcare of Georgia, Atlanta
University of Florida, Gainesville
Orlando Immunology Center, Orlando
University of Miami, Miami
South Florida Center of Gastroenterology, LLC, Wellington
Bach and Godofsky Infectious Diseases, Bradenton
Alabama Liver and Digestive Specialists, Montgomery
Digestive Health Specialists of the Southeast, Dothan
Columbia Medical Group, The Frist Clinic, Nashville
Nashville Medical Research Institute, Nashville
Nashville Gastrointestinal Specialists, Inc, Nashville
Memphis Gastroenterology Group, Germantown
Digestive Health Specialists, PA, Tupelo
Gastrointestinal Associates, PA, Jackson
Graves Gilbert Clinic, Bowling Green
University of Cincinnati, Cincinnati
Indiana University, Indianapolis
Indianapolis Gastroenterology Research Foundation, Indianapolis
Henry Ford Health System, Detroit
Gastroenterology Associates, LLC, Baton Rouge
Options Health Research, LLC, Tulsa
Baylor University Medical Center, Dallas
The North Texas Research Institute, Arlington
Kelsey Research Foundation, Houston
Research Specialists of Texas, Houston
University of Colorado Denver, Aurora
South Denver Gastroenterology, Englewood
Southwest CARE Center, Santa Fe
California Liver Institute, Beverly Hills
RESEARCH and EDUCATION, INC, San Diego
Scripps Clinic, La Jolla
Medical Associates Research Group, San Diego
Kaiser Permanente, San Diego
University of California Davis Medical Center, Sacramento
Virginia Mason Medical Center, Digestive Disease Institute, Seattle
Beth Israel Deaconess Medical Center, Boston
Partners in Internal Medicine, P.C., Worcester
ID Care 105, Hillsborough
Atlantic Research Affiliates, LLC, Morristown
University Gastroenterology, Providence
Fundacion de Investigacion de Diego, San Juan
Lead Sponsor
Gilead Sciences
INDUSTRY